Melatonin is currently considered a promising drug for glaucoma treatment because of its
ocular hypotensive and neuroprotective effects. We have investigated the effect of melatonin …

Melatonin is involved in the control of intraocular pressure during the night and day
photoperiod. We have investigated the receptor that regulates intraocular pressure in New …

Melatonin is a neurohormone that is produced not only by the pineal gland but also by
several ocular structures. One of the main physiologic roles of melatonin is the reduction of …

Melatonin and its analog 5-MCA-NAT (5-methylcarboxyamino-N-acetyl tryptamine) are
active compounds reducing intraocular pressure (IOP). This action is mediated through MT2 …

Glaucoma is a leading cause of blindness. Although ocular hypertension is the most
important risk factor, several concomitant factors such as elevation of glutamate and …

Purpose 5-MCA-NAT, a putative melatonin MT 3 receptor agonist, reduced intraocular
pressure (IOP) in ocular normotensive rabbit eyes. This study evaluates the effect of topical …

Melatonin and its analogue, 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT),
potently reduce intraocular pressure, and may be good candidates for the treatment of …

Melatonin is not only synthesized by the pineal gland but by several ocular structures. This
natural indoleamine is of great importance for regulating several eye processes, among …

We have previously demonstrated that melatonin and its analogue, 5‐
methoxycarbonylamino‐N‐acetyltryptamine (5‐MCA‐NAT), reduce intraocular pressure …

Melatonin, the MT2 melatonin receptor agonist IIK7 [N-butanoyl-2-(2-methoxy-6 H-isoindolo
[2, 1-a] indol-11-yl) ethanamine], and the putative MT3 melatonin receptor agonist 5-MCA …